Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) of Hansa Biopharma AB, effective July 14. Philipson will report to CEO Renée Aguiar-Lucander, who joined the company earlier this year, and be a member of the Executive Committee.

“We are very pleased to welcome Dr Philipson to the executive management team as CMO. He brings invaluable experience in the area of drug development, from first-in-human to Phase 3, and post-approval studies; with expertise across rare diseases, inflammation, and oncology, which will be critical as we prepare for the next phase of our development,” said Aguiar-Lucander.

Experience

Philipson has over 25 years of industry experience and a successful track record in drug development, providing clinical leadership resulting in four product approvals, including in rare disease and gene therapy, and comes with expertise and success in building high-functioning teams, building pipelines, and executing clinical development programs across all phases of development.

He also brings in-depth knowledge of regulatory strategy in drug development. Philipson most recently was CMO of Calliditas Therapeutics and previously spent 16 years at GlaxoSmithKline (GSK), including four years as Therapeutic Area Head in the Rare Diseases Unit. He also has experience from Takeda and a 4-year period as CMO at Trizell.

“I am excited to have the opportunity to join Hansa at this stage of the company’s development. I look forward to working with the Hansa team and leveraging my experience from prior roles to support upcoming regulatory submissions and help build a strategic development plan for future indications,” said Philipson.